Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning

It is not known whether dopamine agonist-induced disruption of prepulse inhibition (PPI) can be conditioned to the environment, a phenomenon established for dopamine agonist-induced locomotor activation and other behaviors. Furthermore, the literature is contradictory regarding whether PPI disruptio...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 2002-07, Vol.162 (2), p.138-146
Main Authors: FEIFEL, David, PRIEBE, Kristianne, JOHNSTONE-MILLER, Elizabeth, MORGAN, Christopher J
Format: Article
Language:English
Subjects:
Acoustic Stimulation
Amphetamine - pharmacology
Analysis of Variance
Animals
Apomorphine - pharmacology
Biological and medical sciences
Catecholaminergic system
Central nervous system
Central neurotransmission. Neuromudulation. Pathways and receptors
Conditioning (Psychology) - drug effects
Dopamine Agonists - pharmacology
Dopamine Antagonists - pharmacology
Dopamine Uptake Inhibitors - pharmacology
Environment
Fundamental and applied biological sciences. Psychology
Haloperidol - pharmacology
Injections, Subcutaneous
Male
Medical sciences
Motor Activity - drug effects
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Rats
Rats, Sprague-Dawley
Reflex, Startle - drug effects
Vertebrates: nervous system and sense organs
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is not known whether dopamine agonist-induced disruption of prepulse inhibition (PPI) can be conditioned to the environment, a phenomenon established for dopamine agonist-induced locomotor activation and other behaviors. Furthermore, the literature is contradictory regarding whether PPI disruption, like locomotor activity, can become sensitized after repeated dopamine agonist administration. Differences in methodology (e.g. drug-environment pairing) may have contributed to these contradictory findings. In a series of studies, we investigated whether dopamine agonist-induced disruption of PPI could be conditioned and whether repeated administration of dopamine agonists, in a paradigm favorable to conditioning, would produce sensitization to dopamine agonist-induced disruption of PPI. One group of rats were administered subcutaneous apomorphine (0.5 mg/kg) daily for 7 (experiment 1) or 5 (experiment 3) consecutive days contingent with startle testing (in testing rooms, immediately before test sessions). A second group received the same apomorphine dose daily in a manner non-contingent with behavioral testing (in home cages after test sessions). The following day, all rats received vehicle injections contingent with the test environment to assess for environmental conditioning (vehicle challenge day). The next day, all animals received a challenge of apomorphine (0.5 mg/kg) contingent with the test environment to assess the contribution of drug-environment pairing on changes observed in apomorphine-induced disruption of PPI (apmorphine challenge day). PPI was measured immediately after drug injections in the test environment. A separate study (experiment 2) tested amphetamine (3.0 mg/kg) using a similar methodology. In a fourth study, rats were pretreated with haloperidol (1.0 mg/kg) or saline prior to receiving daily apomorphine to see if haloperidol could modify the changes in PPI produced by repeated apomorphine administration. On the vehicle challenge day, PPI exhibited by the rats that received daily apomorphine contingent with the testing environment did not differ from the group that received vehicle contingent with the testing environment. However, animals receiving apomorphine contingent with testing exhibited partial tolerance to its PPI effects during the conditioning period. The PPI exhibited by both groups did not differ significantly on the apomorphine-challenge day. Amphetamine produced a complete tolerance to its PPI effects by day 3. Halop
ISSN:0033-3158
1432-2072
DOI:10.1007/s00213-002-1026-1